SEO URLwww.firestrike.ai/deals/rapt-therapeutics-gsk-acquisition-2026-15
acquisitionAnnounced · Jan 21, 2026biopharmaceuticalSource · CredibleArticle · Factual
GSK acquires RAPT Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$2.2B
Target
RAPT Therapeutics
NASDAQ: RAPT · South San Francisco, California
Acquirer
GSK
Full Acquisition
Status
Pending
GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-21. Figures and status may change as filings and press coverage update.
GSK newly announced $2.2 billion acquisition of RAPT Therapeutics reflects a broader industry shift toward immunology assets that pair validated biological targets with improved treatment durability
Deal timeline
Announced
Jan 21, 2026 · biopharminternational.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biopharmaceutical with a reported deal value of $2.2B. Figures and status may change as sources update.
Sources: biopharminternational.com · Primary article · FireStrike proprietary index